Menu

Details of First Three-Parent IVF Revealed

The team that oversaw the first use of mitochondrial replacement therapy that resulted in a live birth has published an account of the procedure.

Apr 3, 2017
Bob Grant

John Zhang with the baby that was the first ever to be born after mitochondrial replacement therapyIMAGE COURTESY OF NEW HOPE FERTILITY CLINIC

Last year, a Jordanian couple became parents to the world’s first-ever baby born through a controversial in vitro fertilization (IVF) technique called mitochondrial replacement therapy (MRT). Now, the doctors who performed the procedure, which involves inserting nuclei from the mothers’ egg cells and into donor ova with healthy mitochondria, have revealed more detail on the conception and resulting live birth. 

John Zhang of the New Hope Fertility Center in New York City and colleagues published an account of the treatment in this month’s issue of Reproductive BioMedicine Online. “Certainly, this is a landmark study,” Dietrich Egli, a stem cell researcher at the New York Stem Cell Foundation, told Nature.

Zhang and colleagues revealed that the mother of the baby boy is a carrier of Lehigh disease, a rare neurometabolic disorder that decimates a child’s muscular system and often results in respiratory failure and death. The authors also described the IVF procedure, including the method they used to transfer the mother’s egg cell nuclei into the donor egg cells. They froze and heated the embryo and then fused the mother’s nuclei into donor ova using an electrical pulse.

In their paper, the researchers also reported that the child carried a 2.36 percent to 9.23 percent mitochondrial DNA (mtDNA) mutational load in samples tested (including hair follicles, circumcised foreskin, and umbilical blood). Because some mutated mtDNA slipped into the embryo, the child may suffer health problems later in life, the authors wrote.

The parents of the child told Zhang and colleagues that they would forgo any mitochondrial testing in their son unless it becomes medically necessary.

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.